Daxor (NYSEMKT:DXR) announces
the first use of its BVA-100 test to guide volume treatment in
COVID-19 patients and released a clinical protocol for fluid guidance
for the same.
The BVA-100 test has been shown in a prospective
randomized control trial to reduce ICU mortality by as much as 66% and
reduce ventilator days in patient populations suffering from respiratory
distress and septic shock.
In addition, the test can help guide precise administration of scarce resources.
Update: Shares are up 16% premarket.
https://seekingalpha.com/news/3553749-daxors-bvaminus-100-test-used-guidance-for-covidminus-19-treatment
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.